AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 26, 2024, discloses the results of the 2024 Annual Meeting of Stockholders held by Aytu BioPharma, Inc. The meeting took place on the same date as the filing. As of the record date (April 29, 2024), there were 5,568,075 shares of common stock issued and outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Approximately 73% of the total issued and outstanding shares were present in person or by proxy, constituting a quorum. All three proposals presented to stockholders were approved:
- Proposal 1 (Election of Directors): All five incumbent directors were elected by a majority vote. Significant broker non-votes (1,329,025) were recorded for each director.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ended June 30, 2024.
- Proposal 3 (Executive Compensation): The non-binding advisory vote on executive compensation was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document serves strictly as a disclosure of the annual meeting vote tabulations.
Key Facts for Investor Verification
- Verify the final vote counts for the five directors, noting the high volume of broker non-votes.
- Confirm the ratification of Grant Thornton LLP as the auditor for the fiscal year ending June 30, 2024.
- Review the Proxy Statement filed on May 10, 2024, for detailed descriptions of the proposals and director biographies.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.